X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs LUPIN LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES LUPIN LTD DIVIS LABORATORIES/
LUPIN LTD
 
P/E (TTM) x 34.1 29.0 117.6% View Chart
P/BV x 6.6 2.8 238.9% View Chart
Dividend Yield % 0.7 0.6 113.1%  

Financials

 DIVIS LABORATORIES   LUPIN LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
LUPIN LTD
Mar-18
DIVIS LABORATORIES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,1421,465 77.9%   
Low Rs533727 73.3%   
Sales per share (Unadj.) Rs146.6349.6 41.9%  
Earnings per share (Unadj.) Rs33.05.6 594.4%  
Cash flow per share (Unadj.) Rs38.429.6 129.8%  
Dividends per share (Unadj.) Rs10.005.00 200.0%  
Dividend yield (eoy) %1.20.5 261.8%  
Book value per share (Unadj.) Rs222.8300.3 74.2%  
Shares outstanding (eoy) m265.47452.08 58.7%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x5.73.1 182.2%   
Avg P/E ratio x25.3197.2 12.9%  
P/CF ratio (eoy) x21.837.1 58.8%  
Price / Book Value ratio x3.83.6 103.0%  
Dividend payout %30.390.0 33.6%   
Avg Mkt Cap Rs m222,318495,502 44.9%   
No. of employees `00010.817.0 63.1%   
Total wages/salary Rs m4,56128,647 15.9%   
Avg. sales/employee Rs Th3,616.09,273.6 39.0%   
Avg. wages/employee Rs Th423.81,681.0 25.2%   
Avg. net profit/employee Rs Th814.9147.4 552.7%   
INCOME DATA
Net Sales Rs m38,915158,042 24.6%  
Other income Rs m1,1341,504 75.5%   
Total revenues Rs m40,049159,545 25.1%   
Gross profit Rs m12,61731,475 40.1%  
Depreciation Rs m1,42510,859 13.1%   
Interest Rs m132,044 0.7%   
Profit before tax Rs m12,31320,076 61.3%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m3,5432,885 122.8%   
Profit after tax Rs m8,7702,513 349.0%  
Gross profit margin %32.419.9 162.8%  
Effective tax rate %28.814.4 200.3%   
Net profit margin %22.51.6 1,417.5%  
BALANCE SHEET DATA
Current assets Rs m45,351122,095 37.1%   
Current liabilities Rs m6,50750,956 12.8%   
Net working cap to sales %99.845.0 221.8%  
Current ratio x7.02.4 290.9%  
Inventory Days Days12785 149.8%  
Debtors Days Days95120 79.3%  
Net fixed assets Rs m21,160129,876 16.3%   
Share capital Rs m531904 58.7%   
"Free" reserves Rs m58,625134,866 43.5%   
Net worth Rs m59,156135,771 43.6%   
Long term debt Rs m064,245 0.0%   
Total assets Rs m67,832263,054 25.8%  
Interest coverage x926.810.8 8,562.2%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.60.6 95.5%   
Return on assets %12.91.7 747.6%  
Return on equity %14.81.9 801.1%  
Return on capital %20.83.7 560.1%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35953,141 60.9%   
Fx outflow Rs m9,04219,335 46.8%   
Net fx Rs m23,31733,807 69.0%   
CASH FLOW
From Operations Rs m7,75917,512 44.3%  
From Investments Rs m-4,783-14,073 34.0%  
From Financial Activity Rs m-3,142-14,921 21.1%  
Net Cashflow Rs m-166-11,482 1.4%  

Share Holding

Indian Promoters % 52.0 46.6 111.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 11.8 11.3 104.4%  
FIIs % 19.0 31.9 59.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.1 170.3%  
Shareholders   31,796 98,259 32.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Dec 11, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS